Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 139 results
“Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes.”, Biol Blood Marrow Transplant, vol. 23, no. 10, pp. 1714-1721, 2017.
, “Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.”, Lancet Haematol, vol. 4, no. 9, pp. e431-e442, 2017.
, “Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial.”, Blood, vol. 128, no. 8, pp. 1050-8, 2016.
, “The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation.”, Biol Blood Marrow Transplant, vol. 22, no. 10, pp. 1747-1757, 2016.
“Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.”, Bone Marrow Transplant, vol. 51, no. 9, pp. 1173-9, 2016.
, “Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis.”, Bone Marrow Transplant, vol. 51, no. 12, pp. 1599-1601, 2016.
, “Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.”, JAMA Oncol, vol. 2, no. 12, pp. 1583-1589, 2016.
, “Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.”, Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
, “Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.”, Biol Blood Marrow Transplant, vol. 22, no. 12, pp. 2256-2263, 2016.
, “Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).”, Cancer, vol. 122, no. 1, pp. 91-8, 2016.
, “Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1108-1116, 2016.
, “Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ”, Biol Blood Marrow Transplant, vol. 22, no. 8, pp. 1440-1448, 2016.
, “Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1133-1137, 2016.
, “Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902 Data.”, Biol Blood Marrow Transplant, vol. 22, no. 11, pp. 2077-2083, 2016.
, “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
, “US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.”, Blood Adv, vol. 1, no. 3, pp. 250-259, 2016.
, “Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.”, J Antimicrob Chemother, vol. 71, no. 8, pp. 2234-40, 2016.
, “Blood and marrow transplant clinical trials network state of the Science Symposium 2014.”, Biol Blood Marrow Transplant, vol. 21, no. 2, pp. 202-24, 2015.
, “Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802.”, Biol Blood Marrow Transplant, vol. 21, no. 6, pp. 1029-36, 2015.
, “Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial.”, Biol Blood Marrow Transplant, vol. 21, no. 10, pp. 1815-22, 2015.
, “Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.”, Lancet Haematol, vol. 2, no. 9, pp. e367-75, 2015.
, “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncolo”, J Clin Oncol, vol. 33, no. 35, pp. 4167-75, 2015.
, “A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.”, Lancet Haematol, vol. 2, no. 1, pp. e21-9, 2015.
, “Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2015.
, “A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.”, Biol Blood Marrow Transplant, vol. 21, no. 4, pp. 761-7, 2015.
,